Cognos Therapeutics Inc. (Cognos) is an advanced medical device company focused on creating unique technologies to radically advance the diagnosis and treatment of neuropathic diseases including tumor-based brain and spinal cancers, degenerative cognition disorders (such as Alzheimer’s and Parkinson’s disease), cerebral trauma occurrences (such as epilepsy and stroke) as well as other Central Nervous System afflictions.
Who We Are
- U.S. Medical Device Company
- Focus on advancing diagnostic and treatment alternatives for neuropathic disease.
- Over 15 years of research and development expertise
- Patented technologies and peer-reviewed publications
- Exceptional management and leadership team
- Recognized engineering, scientific and medical advisory, and technical teams
- Developers of the Sinnais implantable pump technology
BRAIN CANCER FACTS
Brain cancer remains one of the debilitating CNS diseases facing medical providers today. Specifically, high-grade, tumor-based cancers such as Glioblastomas and Anaplastic Astrocytomas pose significant challenges to effective treatment. Inoperable positioning, interconnectivity to healthy tissues, resistance to radiation, and the brain’s natural barrier to chemotherapeutics all make this form of cancer one of the most challenging, and deadly diseases to deal with.
Cognos’ initial focus with the Sinnais implantable pump technology is in providing physicians with a revolutionary method in which to monitor and effectively treat tumor-based brain cancer.
New Adult Diagnosis
Children to be Diagnosed
Avg. 5-year Survival Rate
Sinnais: A Targeted Solution To Brain Cancer
The Sinnais is a standalone, implantable medical device, made with biocompatible and MRI-compatible materials, designed to deliver therapeutic drugs locally and metronomically to a desired area. The first version of the Sinnais will be customized to treat patients affected by leptomeningeal carcinomatosis (LC). LC is a rare complication of cancer in which LC-carrying gliomas metastasize to the membranes surrounding the brain and spinal cord. LC is extremely difficult to treat effectively and if left untreated the median survival is only 4-6 weeks. Unfortunately even when treated with current regimens, the median survival is only 2-3 months. The main three barriers to effective treatment remain:
- LC Gliomas are often very difficult if not impossible to be surgically removed due to size and positioning in the brain.
- The use of systemic or targeted radiation is inefficient in treating LC due to the potential peripheral damage to surrounding healthy tissue and the probability of the tumor having already metastasized to surrounding areas.
- Introduction of IV-based chemotherapeutics cannot effectively penetrate the blood-brain barrier, the network of blood vessels that allows the entry of essential nutrients while blocking all other substances from entering the cerebral matter.
The ability to deliver patient- and tumor-specific targeted chemotherapeutics in microliter resolutions at precisely scheduled intervals based on patients’ personal responses to the therapy and tolerance to the drug dose (biofeedback) directly to a tumor site, represents an evolutionary step forward in the treatment of not only LC but potentially all tumor-based cancers.
- A fully MRI and biocompatible implantable device.
- Metronomic delivery of single or multiple tumor- and patient-specific chemotherapeutic directly to a disease site.
- Adjustable micro-litre delivery of therapeutics based on patient’s reaction and tolerance.
- Proprietary biosensor technology allows physicians to monitor treatment at a site-specific geo-radius.
- Adjustment and monitoring of the device can be done through high-level encrypted wireless network connectivity from anywhere in the world.
- POC and significant pre-commercialization protocols have been completed.